Cyxone presents T20K program at the ECTRIMS conference

Report this content

Cyxone presents the latest results on the T20K project at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Amsterdam.

Cyxone is together with its research collaboration partners at the Medical University of Vienna (MUV) investigating T20K for multiple sclerosis in preclinical research models. Recent discoveries have unveiled that T20K acts as a novel modulator of the k-opioid receptor (KOR). New data from therapeutic preclinical models demonstrated that a combination of T20K and a KOR drug show encouraging positive results: disease progression in animals was delayed, and nerve tissue myelin loss was reduced. The data give support to a new promising concept of a combination therapy. Prof. Christian Gruber, of the Medical University of Vienna will present the data at the ECTRIMS conference in Amsterdam.

“Recent data from our lab show that T20K has activity on immune cells and signaling of the kappa opioid receptor. This established the unique opportunity to explore beneficial effects in disease models of multiple sclerosis. A combination of T20K and a known opioid drug has great potential to become first-in-class disease modifying and remyelinating drug candidate for further studies.” says Dr. Gruber, one of the inventors of the technology and scientific advisor of Cyxone.


ECTRIMS is a non-profit, independent organization that serves as the world’s largest professional organisation dedicated to the understanding and treatment of multiple sclerosis (MS).



Carl-Magnus Högerkorp, acting CEO

Tel: +46 (0)70 781 88 12



About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit



Documents & Links